Pfizer Inc (PFE)
25.40
+0.14
(+0.55%)
USD |
NYSE |
Apr 26, 16:00
25.44
+0.04
(+0.16%)
After-Hours: 20:00
Pfizer Enterprise Value: 201.86B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 26, 2024 | 201.86B |
April 25, 2024 | 201.07B |
April 24, 2024 | 206.77B |
April 23, 2024 | 207.05B |
April 22, 2024 | 206.71B |
April 19, 2024 | 205.25B |
April 18, 2024 | 201.80B |
April 17, 2024 | 201.97B |
April 16, 2024 | 203.49B |
April 15, 2024 | 204.74B |
April 12, 2024 | 204.45B |
April 11, 2024 | 207.17B |
April 10, 2024 | 207.05B |
April 09, 2024 | 209.65B |
April 08, 2024 | 208.52B |
April 05, 2024 | 208.97B |
April 04, 2024 | 208.92B |
April 03, 2024 | 212.13B |
April 02, 2024 | 214.00B |
April 01, 2024 | 214.96B |
March 28, 2024 | 215.13B |
March 27, 2024 | 215.30B |
March 26, 2024 | 214.22B |
March 25, 2024 | 213.32B |
March 22, 2024 | 212.92B |
Date | Value |
---|---|
March 21, 2024 | 214.62B |
March 20, 2024 | 214.84B |
March 19, 2024 | 214.45B |
March 18, 2024 | 214.96B |
March 15, 2024 | 216.20B |
March 14, 2024 | 217.27B |
March 13, 2024 | 217.78B |
March 12, 2024 | 216.60B |
March 11, 2024 | 218.63B |
March 08, 2024 | 212.13B |
March 07, 2024 | 209.71B |
March 06, 2024 | 211.96B |
March 05, 2024 | 205.70B |
March 04, 2024 | 204.62B |
March 01, 2024 | 208.58B |
February 29, 2024 | 208.41B |
February 28, 2024 | 211.12B |
February 27, 2024 | 210.27B |
February 26, 2024 | 211.91B |
February 23, 2024 | 215.18B |
February 22, 2024 | 214.00B |
February 21, 2024 | 214.68B |
February 20, 2024 | 214.22B |
February 16, 2024 | 214.39B |
February 15, 2024 | 213.77B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
247.85B
Average
244.09B
Median
Oct 29 2019
Enterprise Value Benchmarks
Amgen Inc | 198.36B |
Johnson & Johnson | 358.57B |
Eli Lilly and Co | 719.79B |
Viking Therapeutics Inc | 7.231B |
Moderna Inc | 32.74B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -3.369B |
Revenue (Quarterly) | 14.25B |
Total Expenses (Quarterly) | 16.22B |
EPS Diluted (Quarterly) | -0.60 |
Gross Profit Margin (Quarterly) | 46.92% |
Profit Margin (Quarterly) | -23.64% |
Earnings Yield | 1.42% |
Operating Earnings Yield | 2.33% |
Normalized Earnings Yield | 4.191 |